Cure8 research brief
Injection site pain and local reactions can affect comfort and willingness to continue injectable biologic therapy.
This study suggests that switching to AVT02 — a high‑concentration, citrate‑free adalimumab biosimilar — reduced injection site pain and reactions while maintaining adherence and quality-of-life across several conditions including Crohn’s and UC.
Patients with IBD (Crohn’s disease or ulcerative colitis) who are using or considering adalimumab biosimilars, clinicians who prescribe adalimumab, pharmacists, and researchers studying biosimilar switching or injection tolerability.
This Phase IV trial abstract reports that switching patients from reference (low-concentration) adalimumab or another adalimumab biosimilar to AVT02 (a high-concentration, citrate‑free adalimumab biosimilar) reduced injection site pain and injection site reactions, while adherence, satisfaction, and quality-of-life measures remained high over 180 days.
The enrolled population included people with Crohn’s disease, ulcerative colitis, and several rheumatologic and dermatologic conditions. The study used VAS for injection pain, Likert scales for perceived change, EQ-5D-5L for quality of life, and patient/physician global assessments for disease activity.
The abstract presents group-level changes (e.g., mean VAS change and proportions reporting less pain or fewer ISRs) but does not provide full methods, statistical testing details, or safety/adverse event breakdown in this excerpt.
Because the content provided is an abstract-level report, readers should view these findings as preliminary summary results from the published article rather than a full source of trial data.
If considering a treatment switch in clinical practice, discuss with your prescribing clinician whether AVT02’s formulation differences (higher concentration, citrate-free) are relevant to your situation and review full study details and regulatory guidance.
This classification and note are based on the article abstract as provided. The abstract summarizes Phase IV results but does not include full methodological details or comprehensive safety data; consult the full journal article for complete results and context.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
An updated drug label for AMJEVITA affects people with Crohn's disease, ulcerative colitis, and other immune conditions because it defines FDA‑approved uses, dosing schedules (including pediatric dosing), and safety...
This is an official prescribing-label update for an adalimumab biosimilar used to treat Crohn’s disease and ulcerative colitis, including pediatric indications and dosing. Changes to indications or pediatric dosing and...
A new ustekinumab biosimilar (SELARSDI) is now available in the U.S. for Crohn’s disease and ulcerative colitis, which may expand treatment options and affect access or cost for patients on biologic therapy.
